fox files

World Health Organization data show system-wide adverse event reports spanning neurological, cardiac, immune, gastrointestinal, and reproductive categories.

The World Health Organization’s VigiAccess pharmacovigilance database currently lists 5,811,685 individual adverse drug reaction (ADR) reports associated with COVID-19 vaccines as an active ingredient.

A Harvard Pilgrim Healthcare/HHS study confirms fewer than 1% of vaccine adverse events are reported, meaning the number could be closer to half a billion.

These reports are submitted by national drug regulators worldwide and categorized by affected body system.

Below is the full numerical breakdown exactly as listed in the database.

---

Reported Potential Side Effects by System Category

• General disorders and administration site conditions
  3,435,222 reports (26%)
• Nervous system disorders
  2,162,680 reports (16%)
• Gastrointestinal disorders
  969,611 reports (7%)
• Investigations (laboratory abnormalities, diagnostic findings)
  807,850 reports (6%)
• Infections and infestations
  660,107 reports (5%)
• Respiratory, thoracic, and mediastinal disorders
  559,163 reports (4%)
• Skin and subcutaneous tissue disorders
  643,195 reports (5%)
• Injury, poisoning, and procedural complications
  373,950 reports (3%)
• Cardiac disorders
  334,064 reports (3%)
• Psychiatric disorders
  253,443 reports (2%)
• Blood and lymphatic system disorders
  240,517 reports (2%)
• Vascular disorders
  245,846 reports (2%)
• Reproductive system and breast disorders
  280,795 reports (2%)
• Musculoskeletal and connective tissue disorders
  1,419,363 reports (11%)
• Immune system disorders
  123,050 reports (1%)
• Surgical and medical procedures
  121,374 reports (1%)
• Metabolism and nutrition disorders
  103,797 reports (1%)
• Eye disorders
  172,469 reports (1%)
• Ear and labyrinth disorders
  153,026 reports (1%)

Lower-Frequency Categories Still Numerically Significant

• Renal and urinary disorders
  47,767 reports
• Endocrine disorders
  13,403 reports
• Hepatobiliary disorders
  13,323 reports
• Pregnancy, puerperium, and perinatal conditions
  14,180 reports
• Congenital, familial, and genetic disorders
  4,533 reports
• Neoplasms (benign, malignant, unspecified)
  17,770 reports
• Product issues
  10,919 reports
• Social circumstances
  47,909 reports

These figures represent submissions from national health authorities participating in the WHO’s global drug-safety monitoring program.

As of March 2025, 182 health authorities (national pharmacovigilance centers) participate in the WHO Program for International Drug Monitoring.

Each report may include multiple symptoms, meaning totals by category exceed the number of individual reports.

The scale and system-wide distribution of these reports are unprecedented for a single pharmaceutical product class in the VigiBase system.